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remitting course (Table), they had experienced a higher than
expected relapse rate of 0.9/year. However, the patients in our
population had MS associated with CCSVI. For this peculiar
association, we measured in our pilot study if angioplasty treat-
ment of CCSVI could modify the neurologic outcome of MS.
The endovascular treatment, despite the 47% restenosis rate
recorded in the internal jugular veins, reduced, although not
significantly, the annualized relapse rate from 0.9 to 0.7. Relapse
did recur in 50% of patients compared with 77% registered in the
previous 2 years (P  .0014). As stated in the article, relapses as
well as new T1 gadolinium-positive lesions did not occur in pa-
tients with patency of the major cerebral veins: two objectively
measured facts and not a sham effect. Actually, we are conducting
long-term follow-up of the same cohort.
We think it would be highly irresponsible to not report to
colleagues such preliminary results. The excitement is understand-
able for patients and is linked to two reasons. The first is the
awareness that MS, ranging from 56% to 100% of cases, can be
associated with a major vascular problem.2,4-6 The second is that
the latter may have a resolution through a minimally invasive
surgery.
Knowing if this is a sham or a real therapeutic effect for MS is
a precise responsibility of the medical community, and not an
opinion expressed in a scientific letter. As stated on page 1357 line
35, a randomized, controlled, double-blind study is the only tool
that can answer the question of Dr Requarth. This will start in the
next months involving several centers in Italy.
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Regarding “A prospective open-label study of
endovascular treatment of chronic cerebrospinal
venous insufficiency”
In the article “A prospective open-label study of endovascular
treatment of chronic cerebrospinal venous insufficiency,” by Zam-
boni et al,1 the authors compared pre- and post-therapy outcomes
with two-sample statistical analyses as though the outcomes arose
from independent groups of patients (page 1351 of the article).
They did not present within-patient results or use paired statistical
tests for change in venous pressure or neurologic outcomes. Their
reported use of Fisher exact test to analyze annualized relapse rates
is not appropriate because those data are not proportions or
numbers of patients. Tables IV and V fail to state the number of
patients included in these results. Onemight suspect that not all 35
relapsing remitting patients contribute to Table IV, as no counts
yield percentages of 27% (9: 26%, 10: 29%) or 50% (17: 49%, 18:
51%), for example.
Given the attention that Dr Zamboni’s results have received,
the reader would welcome an addendum with clarification and
information that is more complete. It is possible that the appropri-
ate paired testing would provide similar or greater degrees of
statistical significance, bolstering hope for the effectiveness of
percutaneous transluminal angioplasty in treating multiple sclero-
sis patients.
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Reply
Our study is a pilot study with promising results. It shows two
main shortcomings: the lack of a control group and blinded clinical
assessors. We chose to use statistical tests to underestimate rather
than exalt our findings, precisely because of the above limitations.
The tests suggested by you, as you noted at the end of your letter,
provide even greater degrees of statistical significance. Our policy is
to be as prudent as we can, waiting for randomized control trial
angioplasty results. The main message of our study is the safety and
the feasibility of venous angioplasty in patients affected by chronic
cerebrospinal venous insufficiency associated with multiple sclero-
sis (CCSVI-MS).1
However, differences in quality of life and multiple sclerosis
functional composite among neurologic outcomes were re-assessed
also with paired t test, as you requested in your letter, and were
significantly different. For instance, MSFC in relapsing remitting
patients by comparing baselinewith 18months value showed a highly
significant improvement of the motor and cognitive function ex-
pressed by such functional composite test (P .0001).
Differences in preoperative and postoperative pressure were
assessed with the two-tailed Mann-Whitney test, as reported at
page 1351 of our article.1
